Gracell Biotechnologies To Present Data Highlighting Preclinical Efficacy Of SMART CART Against Solid Tumors At Society For Immunotherapy Of Cancer 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Gracell Biotechnologies Inc. (NASDAQ:GRCL) will present preclinical data from its SMART CART technology for solid tumors at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The technology is designed to enhance CAR-T cell proliferation and persistence in suppressive tumor microenvironments (TMEs). The company will also launch an investigator-initiated trial of SMART CART GC506 targeting Claudin 18.2 positive tumors.
October 31, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gracell Biotechnologies is set to present promising preclinical data on its SMART CART technology, which could potentially enhance the effectiveness of CAR-T therapy against solid tumors. This could potentially boost investor confidence in the company's innovative approach to cancer treatment.
The presentation of promising preclinical data on Gracell's SMART CART technology could potentially boost investor confidence in the company's innovative approach to cancer treatment. The launch of a trial for SMART CART GC506 also indicates progress in the company's research and development efforts, which could positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100